

ASX Announcement

29 September 2020

Regeneus receives A\$676k in R&D Tax Incentives

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, has received \$676k in R&D Tax Incentives from the Australian Tax Office for FY20.

The cash rebate from the Australian Tax Office is related to eligible Australian R&D activities during the financial year.

Receipt of the rebate strengthens Regeneus' cash balance prior to the next milestone payment from Kyocera which is expected shortly.

Regeneus is well positioned to continue commercialization of its lead platform technology Progenza in Japan and other territories.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com